title: In vitro thermo-chemosensitivity screening of spontaneous human tumors: significant potentiation for cisplatin but not adriamycin.
abstract: The in vitro thermal enhancement of Adriamycin (ADR) and Cisplatin (CDDP) was investigated in 18 surgical biopsy specimens of human tumors cultured in the Adhesive Tumor Cell Culture System. Experimental conditions were adopted to simulate "therapeutic" trials: (a) temperature of 37.0 degrees C, 40.5 degrees C or 42.5 degrees C; (b) hyperthermic duration of 30, 60, or 120 min; and (c) 4-dose drug range normalized to human bone marrow toxicity. Drug concentrations that inhibited 90% of tumor growth (IC90) at 37.0 degrees C were compared to the IC90 at 40.5 degrees C and 42.5 degrees C, adjusted for the effect of heat alone. CDDP plus heat was a better combination than ADR plus heat, regardless of the temperature and the exposure duration: significant synergism (p less than 0.001) occurred in 37% of heat-CDDP combinations, as compared with 15% of heat-ADR combinations, and antagonism was significantly lower (p less than 0.001) for heat-CDDP than for heat-ADR (4.4% versus 21% of combinations, respectively). Within the CDDP group, higher temperature and longer heat exposure resulted in an increased incidence of chemosensitivity. No specific pattern of synergism was evident within the ADR group, but a trend toward a higher incidence of antagonistic effects with increasing hyperthermic duration was observed.
authors.affiliation: Department of General Surgery, Regina Elena Cancer Institute, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Calabro
authors.forename: S E
authors.initials: SE
authors.lastname: Singletary
authors.forename: S
authors.initials: S
authors.lastname: Tucker
authors.forename: A
authors.initials: A
authors.lastname: Boddie
authors.forename: G
authors.initials: G
authors.lastname: Spitzer
authors.forename: R
authors.initials: R
authors.lastname: Cavaliere
mesh_terms: D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006979:Hyperthermia, Induced; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured
chemical_list: D004317:Doxorubicin; D002945:Cisplatin